These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21418965)

  • 1. [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
    Hou X; Zhao Y; Zheng YR; Wang JJ; Wu ZC; Sun JH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(1):56-8. PubMed ID: 21418965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
    Wang HW; Xu ZK; Song Y; Liu YG
    Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
    Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
    Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
    Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
    Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
    Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
    Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New (alternative) temozolomide regimens for the treatment of glioma.
    Wick W; Platten M; Weller M
    Neuro Oncol; 2009 Feb; 11(1):69-79. PubMed ID: 18772354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
    Tanaka S; Kamitani H; Amin MR; Watanabe T; Oka H; Fujii K; Nagashima T; Hori T
    J Neurooncol; 2000; 46(2):157-71. PubMed ID: 10894369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
    Tanaka S; Akimoto J; Kobayashi I; Oka H; Ujiie H
    Oncol Rep; 2008 Jul; 20(1):165-71. PubMed ID: 18575733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.